Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen NEUPOGEN (filgrastim by Year
NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)
Amgen NEUPOGEN (filgrastim: -14.0% in FY2022, up 11.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2022 figure comes from
“|| NEUPOGEN ® | 87 | 57 | 144 | 168 | (14%)”
Source: Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Reported in Form 8-K Product Sales Detail by Product and Geographic Region.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | -14.0% | +11.0 pts | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | -25.0% | -10.0 pts | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | -15.0% | +13.0 pts | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | -28.0% | +6.0 pts | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
| FY2018 | Dec 31, 2018 | -34.0% | – | Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗ |
Cite this data
StockData. (2026). Amgen NEUPOGEN (filgrastim (%), annual FY2018–FY2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-neupogen-yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.